Total Payments
$2,016
2024 Payments
$171.83
Companies
13
Transactions
26
Medicare Patients
4,823
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$2,016 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,016 | 26 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic Vascular, Inc. | $394.25 | 2 | $0 (2018) |
| Allergan Inc. | $240.12 | 3 | $0 (2018) |
| Genentech USA, Inc. | $197.72 | 4 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $183.31 | 5 | $0 (2023) |
| Ivantis, Inc | $151.52 | 1 | $0 (2019) |
| ABBVIE INC. | $125.85 | 3 | $0 (2023) |
| Shire North American Group Inc | $121.85 | 1 | $0 (2017) |
| Alcon Vision LLC | $121.83 | 1 | $0 (2024) |
| Johnson & Johnson Surgical Vision, Inc. | $117.76 | 1 | $0 (2021) |
| Aerie Pharmaceuticals, Inc. | $116.44 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $171.83 | 3 | Alcon Vision LLC ($121.83) |
| 2023 | $206.72 | 7 | ABBVIE INC. ($125.85) |
| 2022 | $215.46 | 2 | Genentech USA, Inc. ($132.51) |
| 2021 | $130.60 | 2 | Johnson & Johnson Surgical Vision, Inc. ($117.76) |
| 2020 | $29.81 | 2 | Regeneron Healthcare Solutions, Inc. ($29.81) |
| 2019 | $389.01 | 3 | Ivantis, Inc ($151.52) |
| 2018 | $448.82 | 4 | Medtronic Vascular, Inc. ($196.52) |
| 2017 | $423.84 | 3 | Medtronic Vascular, Inc. ($197.73) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $30.66 | General |
| Category: IMMUNOLOGY | ||||||
| 07/07/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Ophthalmology | ||||||
| 05/08/2024 | Alcon Vision LLC | Clareon (Device) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Ophthalmology | ||||||
| 10/04/2023 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: EYE CARE | ||||||
| 06/29/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/27/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/21/2023 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: EYE CARE | ||||||
| 04/19/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/14/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: OPHTHALMOLOGY | ||||||
| 01/12/2023 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $83.94 | General |
| Category: EYE CARE | ||||||
| 10/19/2022 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $82.95 | General |
| 05/02/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $132.51 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/01/2021 | Johnson & Johnson Surgical Vision, Inc. | Tecnis IOL (Device) | Food and Beverage | In-kind items and services | $117.76 | General |
| Category: Optics | ||||||
| 08/20/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $12.84 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/08/2020 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/17/2020 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2019 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/23/2019 | Ivantis, Inc | Hydrus (Device) | Food and Beverage | In-kind items and services | $151.52 | General |
| Category: Ophthalmic Surgery | ||||||
| 08/22/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $112.49 | General |
| 11/15/2018 | Medtronic Vascular, Inc. | Endurant (Device) | Food and Beverage | In-kind items and services | $196.52 | General |
| Category: Aortic Stent Grafts | ||||||
| 08/16/2018 | Aerie Pharmaceuticals, Inc. | Rhopressa (Drug) | Food and Beverage | In-kind items and services | $116.44 | General |
| Category: Ophthalmology | ||||||
| 04/12/2018 | Allergan Inc. | LUMIGAN (Drug), COMBIGAN | Food and Beverage | In-kind items and services | $115.31 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/23/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $20.55 | General |
| 11/15/2017 | Medtronic Vascular, Inc. | Endurant (Device) | Food and Beverage | In-kind items and services | $197.73 | General |
| Category: Aortic Stent Grafts | ||||||
| 10/05/2017 | Shire North American Group Inc | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $121.85 | General |
| Category: OPTHALMICS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,349 | 2,950 | $1.1M | $306,006 |
| 2022 | 11 | 1,055 | 2,565 | $1.0M | $311,874 |
| 2021 | 12 | 1,309 | 2,826 | $1.0M | $298,869 |
| 2020 | 11 | 1,110 | 2,407 | $858,300 | $239,491 |
Total Patients
4,823
Total Services
10,748
Medicare Billing
$1.2M
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 26 | 230 | $287,500 | $158,139 | 55.0% |
| 67028 | Injection of drug into eye | Office | 2023 | 112 | 495 | $374,250 | $40,955 | 10.9% |
| 92134 | Imaging of retina | Office | 2023 | 376 | 987 | $197,400 | $28,226 | 14.3% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 217 | 348 | $52,200 | $21,480 | 41.1% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 89 | 314 | $47,100 | $20,312 | 43.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 152 | 174 | $34,800 | $11,598 | 33.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 89 | 104 | $20,800 | $9,119 | 43.8% |
| 92250 | Photography of the retina | Office | 2023 | 168 | 168 | $16,800 | $4,855 | 28.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $9,300 | $3,801 | 40.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 36 | 37 | $18,500 | $3,448 | 18.6% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 12 | 14 | $18,000 | $2,735 | 15.2% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 14 | 20 | $3,000 | $812.49 | 27.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 27 | 28 | $1,400 | $524.88 | 37.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 27 | 254 | $317,500 | $182,180 | 57.4% |
| 67028 | Injection of drug into eye | Office | 2022 | 98 | 466 | $349,500 | $38,278 | 11.0% |
| 92134 | Imaging of retina | Office | 2022 | 345 | 891 | $178,200 | $25,490 | 14.3% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 239 | 345 | $51,750 | $21,481 | 41.5% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 75 | 292 | $43,800 | $19,396 | 44.3% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 154 | 196 | $39,200 | $15,854 | 40.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $7,800 | $3,511 | 45.0% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 32 | 32 | $16,000 | $2,904 | 18.2% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 12 | 12 | $3,000 | $1,295 | 43.2% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 16 | 20 | $3,000 | $873.39 | 29.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 31 | 31 | $1,550 | $610.69 | 39.4% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 24 | 200 | $250,000 | $142,463 | 57.0% |
About Dr. Jasmine Elison, M.D
Dr. Jasmine Elison, M.D is a Retina Specialist healthcare provider based in Metairie, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740219583.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jasmine Elison, M.D has received a total of $2,016 in payments from pharmaceutical and medical device companies, with $171.83 received in 2024. These payments were reported across 26 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($2,016).
As a Medicare-enrolled provider, Elison has provided services to 4,823 Medicare beneficiaries, totaling 10,748 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Location Metairie, LA
- Active Since 07/02/2006
- Last Updated 05/01/2020
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1740219583
Products in Payments
- Endurant (Device) $394.25
- EYLEA (Biological) $183.31
- Hydrus (Device) $151.52
- VABYSMO (Drug) $132.51
- XIIDRA (Drug) $121.85
- Clareon (Device) $121.83
- Tecnis IOL (Device) $117.76
- Rhopressa (Drug) $116.44
- LUMIGAN (Drug) $115.31
- DURYSTA (Drug) $83.94
- Vabysmo (Drug) $65.21
- OZURDEX (Drug) $41.91
- ACTHAR (Biological) $30.66
- Syfovre (Drug) $19.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.